NORTH KINGSTOWN, R.I., June 8, 2011 /PRNewswire/ — Leading
national medication monitoring company, Dominion Diagnostics,
announces its support of Tufts Health Care Institute’s (THCI)
Program on Opioid Risk Management for a fourth consecutive
year.
Dominion’s support of THCI’s Program on Opioid Risk Management
began in 2007 as part of the company’s commitment to promoting the
safe and effective use of controlled opioid medications commonly
prescribed for chronic pain patients. The Program aims to
address the need to provide chronic pain patients with adequate
opioid pharmacotherapy that enhances individual patient care while
simultaneously reducing the risk of abuse and/or diversion.
“The mission of THCI’s Opioid Risk Management Program is
paramount to raising the standard of care for chronic pain patients
and addressing the rapidly growing epidemic of prescription drug
misuse,” says Bob Garvey, Dominion’s Chief Executive Officer. “It
has become essential to engage such a diverse group of stakeholders
in the development and implementation of programs that support
prescription adherence, improve patient outcomes, and minimize risk
through education, innovative clinical support, and evidence-based
quality care.”
Through a series of summit meetings each year, the THCI Opioid
Risk Management Program provides a unique educational forum to
encourage discussion among industry thought leaders. Summit
meeting participants, including Dominion’s representatives, review
scientific and health industry findings relevant to opioid risk
management, and discuss recommendations for future initiatives. The
THCI Opioid Risk Management Program has distinguished itself
nationally as a high value medium for its exchange of ideas,
implementation of awareness goals, and resulting collaborations for
research and publication.
Dominion will participate in a two-day summit this week that
will focus on pharmacotherapy for prescription opioid
addiction
‘/>”/>
